HTRA2 and Parkinson disease: The findings of pUbSer65, LonP1, HTRA2 and PGC-1α were further confirmed using linear mixed effects modelling for the significant changes (*p < 0.05, 6/8 PD cases analysed, Fig. 6e–g).